25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ATRA (Atara Biotherapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Atara Biotherapeutics Inc together

I guess you are interested in Atara Biotherapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Atara Biotherapeutics Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Atara Biotherapeutics Inc’s Price Targets

I'm going to help you getting a better view of Atara Biotherapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Atara Biotherapeutics Inc

I send you an email if I find something interesting about Atara Biotherapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Atara Biotherapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Atara Biotherapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
7.5%

What is your share worth?

Current worth
$-5.08
Expected worth in 1 year
$6.34
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$11.42
Return On Investment
138.4%

For what price can you sell your share?

Current Price per Share
$8.25
Expected price per share
$6.2474 - $18.25
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Atara Biotherapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$8.25
Intrinsic Value Per Share
$-224.68 - $455.65
Total Value Per Share
$-229.76 - $450.58

2.2. Growth of Atara Biotherapeutics Inc (5 min.)




Is Atara Biotherapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$55m-$60.2m-$28.2m-31.9%

How much money is Atara Biotherapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$3.9m-$582.7m$578.8m14,803.6%
Net Profit Margin-30.3%-30,581.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Atara Biotherapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#856 / 884

Most Revenue
#147 / 884

Most Profit
#376 / 884

Most Efficient
#459 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Atara Biotherapeutics Inc?

Welcome investor! Atara Biotherapeutics Inc's management wants to use your money to grow the business. In return you get a share of Atara Biotherapeutics Inc.

First you should know what it really means to hold a share of Atara Biotherapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Atara Biotherapeutics Inc is $8.25. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Atara Biotherapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Atara Biotherapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-5.08. Based on the TTM, the Book Value Change Per Share is $2.85 per quarter. Based on the YOY, the Book Value Change Per Share is $-6.85 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Atara Biotherapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps3.5042.5%-0.93-11.3%-44.58-540.3%-18.17-220.3%-16.45-199.4%-11.76-142.5%
Usd Book Value Change Per Share4.0348.8%2.8534.6%-6.85-83.0%-3.56-43.1%-2.37-28.8%-0.82-10.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share4.0348.8%2.8534.6%-6.85-83.0%-3.56-43.1%-2.37-28.8%-0.82-10.0%
Usd Price Per Share5.94-8.97-1.07-4.83-8.90-17.14-
Price to Earnings Ratio0.42--0.94--0.02--0.28--0.28--0.81-
Price-to-Total Gains Ratio1.48-0.45-1.03-0.53--0.33--2.22-
Price to Book Ratio-1.17--0.94-0.26--0.17-0.01-0.28-
Price-to-Total Gains Ratio1.48-0.45-1.03-0.53--0.33--2.22-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share8.25
Number of shares121
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share2.85-2.37
Usd Total Gains Per Share2.85-2.37
Gains per Quarter (121 shares)345.32-287.15
Gains per Year (121 shares)1,381.27-1,148.59
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10138113711-1149-1159
20276327521-2298-2308
30414441332-3447-3457
40552555142-4597-4606
50690668953-5746-5755
60828882763-6895-6904
70966996574-8044-8053
8011050110384-9193-9202
9012431124195-10342-10351
10013813138006-11491-11500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%2.038.00.05.0%2.044.00.04.3%
Book Value Change Per Share3.01.00.075.0%5.07.00.041.7%7.013.00.035.0%11.029.00.027.5%14.032.00.030.4%
Dividend per Share0.00.04.00.0%3.00.09.025.0%3.00.017.015.0%3.00.037.07.5%3.00.043.06.5%
Total Gains per Share3.01.00.075.0%5.07.00.041.7%7.013.00.035.0%11.029.00.027.5%14.032.00.030.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Atara Biotherapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--4.0252.854+41%-6.847+270%-3.559+188%-2.374+159%-0.823+120%
Book Value Per Share---5.075-11.088+118%-10.103+99%1.830-377%24.096-121%36.229-114%
Current Ratio--0.5680.515+10%1.279-56%1.952-71%3.571-84%11.285-95%
Debt To Asset Ratio--1.8881.840+3%1.358+39%1.262+50%0.863+119%0.476+296%
Debt To Equity Ratio----0%8.015-100%3.279-100%2.124-100%1.113-100%
Dividend Per Share----0%0.000-100%0.002-100%0.001-100%0.001-100%
Enterprise Value---38814060.000-76604270.000+97%-156751274.862+304%-52451208.912+35%105940826.043-137%250607966.986-115%
Eps--3.503-0.930+127%-44.575+1373%-18.173+619%-16.451+570%-11.756+436%
Ev To Ebitda Ratio---0.2380.940-125%0.871-127%0.442-154%-0.167-30%-1.772+646%
Ev To Sales Ratio---0.099-0.537+443%-12.271+12312%-2.748+2680%2.633-104%2.633-104%
Free Cash Flow Per Share---2.593-1.791-31%-7.763+199%-6.348+145%-7.458+188%-6.778+161%
Free Cash Flow To Equity Per Share---2.616-0.619-76%-6.676+155%-5.127+96%-2.302-12%-0.927-65%
Gross Profit Margin--1.0001.0000%1.0020%1.0010%1.0000%1.0000%
Intrinsic Value_10Y_max--455.652----------
Intrinsic Value_10Y_min---224.685----------
Intrinsic Value_1Y_max---15.129----------
Intrinsic Value_1Y_min---26.501----------
Intrinsic Value_3Y_max--0.872----------
Intrinsic Value_3Y_min---76.644----------
Intrinsic Value_5Y_max--72.726----------
Intrinsic Value_5Y_min---123.136----------
Market Cap49181467.500-31%64454940.00079913230.000-19%6403725.138+907%37590207.754+71%58328426.043+11%104835116.986-39%
Net Profit Margin--0.387-0.303+178%-305.816+79068%-449.472+116162%-311.739+80597%-155.870+40348%
Operating Margin--0.398-0.270+168%-30.747+7833%-46.550+11807%-32.163+8189%-16.082+4144%
Operating Ratio--0.6051.289-53%31.170-98%48.085-99%34.948-98%17.474-97%
Pb Ratio-1.626-39%-1.170-0.944-19%0.260-550%-0.168-86%0.005-21664%0.282-514%
Pe Ratio0.589+28%0.424-0.939+322%-0.017+104%-0.282+167%-0.278+166%-0.807+290%
Price Per Share8.250+28%5.9408.970-34%1.074+453%4.827+23%8.897-33%17.142-65%
Price To Free Cash Flow Ratio-0.795-39%-0.573-1.762+208%-0.034-94%-0.637+11%-0.824+44%-1.364+138%
Price To Total Gains Ratio2.050+28%1.4760.447+230%1.025+44%0.530+178%-0.326+122%-2.218+250%
Quick Ratio--0.4740.446+6%1.647-71%2.889-84%5.702-92%19.650-98%
Return On Assets--0.6130.045+1259%-3.039+596%-1.524+349%-1.636+367%-1.482+342%
Return On Equity----0%-23.8490%-9.7140%-6.8470%-4.1740%
Total Gains Per Share--4.0252.854+41%-6.847+270%-3.557+188%-2.373+159%-0.823+120%
Usd Book Value---55072000.000-88440500.000+61%-60230750.000+9%3458916.667-1692%139177600.000-140%213740550.000-126%
Usd Book Value Change Per Share--4.0252.854+41%-6.847+270%-3.559+188%-2.374+159%-0.823+120%
Usd Book Value Per Share---5.075-11.088+118%-10.103+99%1.830-377%24.096-121%36.229-114%
Usd Dividend Per Share----0%0.000-100%0.002-100%0.001-100%0.001-100%
Usd Enterprise Value---38814060.000-76604270.000+97%-156751274.862+304%-52451208.912+35%105940826.043-137%250607966.986-115%
Usd Eps--3.503-0.930+127%-44.575+1373%-18.173+619%-16.451+570%-11.756+436%
Usd Free Cash Flow---28138000.000-16840500.000-40%-46277750.000+64%-39899166.667+42%-45696050.000+62%-41023800.000+46%
Usd Free Cash Flow Per Share---2.593-1.791-31%-7.763+199%-6.348+145%-7.458+188%-6.778+161%
Usd Free Cash Flow To Equity Per Share---2.616-0.619-76%-6.676+155%-5.127+96%-2.302-12%-0.927-65%
Usd Market Cap49181467.500-31%64454940.00079913230.000-19%6403725.138+907%37590207.754+71%58328426.043+11%104835116.986-39%
Usd Price Per Share8.250+28%5.9408.970-34%1.074+453%4.827+23%8.897-33%17.142-65%
Usd Profit--38010000.000-3910250.000+110%-582767500.000+1633%-374699250.000+1086%-555498050.000+1561%-488195275.000+1384%
Usd Revenue--98149000.00049933000.000+97%8676000.000+1031%24326750.000+303%33888350.000+190%16944175.000+479%
Usd Total Gains Per Share--4.0252.854+41%-6.847+270%-3.557+188%-2.373+159%-0.823+120%
 EOD+4 -4MRQTTM+23 -12YOY+30 -93Y+26 -135Y+21 -1810Y+20 -19

3.3 Fundamental Score

Let's check the fundamental score of Atara Biotherapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.589
Price to Book Ratio (EOD)Between0-1-1.626
Net Profit Margin (MRQ)Greater than00.387
Operating Margin (MRQ)Greater than00.398
Quick Ratio (MRQ)Greater than10.474
Current Ratio (MRQ)Greater than10.568
Debt to Asset Ratio (MRQ)Less than11.888
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.613
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Atara Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.593
Ma 20Greater thanMa 508.339
Ma 50Greater thanMa 1007.737
Ma 100Greater thanMa 2007.319
OpenGreater thanClose7.880
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Fundamental data was last updated by Penke on 2025-06-19 00:08:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Atara Biotherapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Atara Biotherapeutics Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 38.7%Β means thatΒ $0.39 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Atara Biotherapeutics Inc:

  • The MRQ is 38.7%. The company is making a huge profit. +2
  • The TTM is -30.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ38.7%TTM-30.3%+69.0%
TTM-30.3%YOY-30,581.6%+30,551.4%
TTM-30.3%5Y-31,173.9%+31,143.6%
5Y-31,173.9%10Y-15,587.0%-15,587.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ38.7%-92.7%+131.4%
TTM-30.3%-141.4%+111.1%
YOY-30,581.6%-186.1%-30,395.5%
3Y-44,947.2%-248.3%-44,698.9%
5Y-31,173.9%-338.6%-30,835.3%
10Y-15,587.0%-488.9%-15,098.1%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Atara Biotherapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Atara Biotherapeutics Inc to theΒ Biotechnology industry mean.
  • 61.3% Return on Assets means thatΒ Atara Biotherapeutics Inc generatedΒ $0.61 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Atara Biotherapeutics Inc:

  • The MRQ is 61.3%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 4.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ61.3%TTM4.5%+56.8%
TTM4.5%YOY-303.9%+308.4%
TTM4.5%5Y-163.6%+168.1%
5Y-163.6%10Y-148.2%-15.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ61.3%-11.5%+72.8%
TTM4.5%-11.6%+16.1%
YOY-303.9%-11.4%-292.5%
3Y-152.4%-11.8%-140.6%
5Y-163.6%-12.1%-151.5%
10Y-148.2%-13.8%-134.4%
4.3.1.3. Return on Equity

Shows how efficient Atara Biotherapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Atara Biotherapeutics Inc to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Atara Biotherapeutics Inc generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-2,384.9%+2,384.9%
TTM-5Y-684.7%+684.7%
5Y-684.7%10Y-417.4%-267.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.6%+13.6%
TTM--14.9%+14.9%
YOY-2,384.9%-14.4%-2,370.5%
3Y-971.4%-17.0%-954.4%
5Y-684.7%-17.9%-666.8%
10Y-417.4%-20.1%-397.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Atara Biotherapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Atara Biotherapeutics Inc is operatingΒ .

  • Measures how much profit Atara Biotherapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Atara Biotherapeutics Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 39.8%Β means the company generated $0.40 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Atara Biotherapeutics Inc:

  • The MRQ is 39.8%. The company is operating very efficient. +2
  • The TTM is -27.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ39.8%TTM-27.0%+66.7%
TTM-27.0%YOY-3,074.7%+3,047.7%
TTM-27.0%5Y-3,216.3%+3,189.4%
5Y-3,216.3%10Y-1,608.2%-1,608.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ39.8%-229.2%+269.0%
TTM-27.0%-250.3%+223.3%
YOY-3,074.7%-205.1%-2,869.6%
3Y-4,655.0%-220.2%-4,434.8%
5Y-3,216.3%-342.6%-2,873.7%
10Y-1,608.2%-475.5%-1,132.7%
4.3.2.2. Operating Ratio

Measures how efficient Atara Biotherapeutics Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.60 means that the operating costs are $0.60 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.605. The company is efficient in keeping operating costs low. +1
  • The TTM is 1.289. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.605TTM1.289-0.684
TTM1.289YOY31.170-29.881
TTM1.2895Y34.948-33.659
5Y34.94810Y17.474+17.474
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6052.110-1.505
TTM1.2892.704-1.415
YOY31.1703.063+28.107
3Y48.0853.576+44.509
5Y34.9484.713+30.235
10Y17.4746.512+10.962
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Atara Biotherapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.57Β means the company has $0.57 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.568. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.515. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.568TTM0.515+0.053
TTM0.515YOY1.279-0.764
TTM0.5155Y3.571-3.056
5Y3.57110Y11.285-7.713
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5683.661-3.093
TTM0.5153.786-3.271
YOY1.2794.121-2.842
3Y1.9524.680-2.728
5Y3.5715.765-2.194
10Y11.2856.150+5.135
4.4.3.2. Quick Ratio

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Atara Biotherapeutics Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.47Β means the company can pay off $0.47 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.474. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.446. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.474TTM0.446+0.028
TTM0.446YOY1.647-1.201
TTM0.4465Y5.702-5.256
5Y5.70210Y19.650-13.948
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4742.826-2.352
TTM0.4463.128-2.682
YOY1.6473.782-2.135
3Y2.8894.304-1.415
5Y5.7025.703-0.001
10Y19.6506.454+13.196
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Atara Biotherapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Atara Biotherapeutics IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Atara Biotherapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.89Β means that Atara Biotherapeutics Inc assets areΒ financed with 188.8% credit (debt) and the remaining percentage (100% - 188.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 1.888. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.840. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.888TTM1.840+0.048
TTM1.840YOY1.358+0.481
TTM1.8405Y0.863+0.977
5Y0.86310Y0.476+0.387
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8880.324+1.564
TTM1.8400.347+1.493
YOY1.3580.327+1.031
3Y1.2620.339+0.923
5Y0.8630.349+0.514
10Y0.4760.382+0.094
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Atara Biotherapeutics Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Atara Biotherapeutics Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY8.015-8.015
TTM-5Y2.124-2.124
5Y2.12410Y1.113+1.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.383-0.383
TTM-0.436-0.436
YOY8.0150.410+7.605
3Y3.2790.446+2.833
5Y2.1240.460+1.664
10Y1.1130.509+0.604
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Atara Biotherapeutics Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Atara Biotherapeutics Inc to theΒ Biotechnology industry mean.
  • A PE ratio of 0.42 means the investor is paying $0.42Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is 0.589. Based on the earnings, the company is cheap. +2
  • The MRQ is 0.424. Based on the earnings, the company is cheap. +2
  • The TTM is -0.939. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.589MRQ0.424+0.165
MRQ0.424TTM-0.939+1.363
TTM-0.939YOY-0.017-0.922
TTM-0.9395Y-0.278-0.661
5Y-0.27810Y-0.807+0.529
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.589-2.197+2.786
MRQ0.424-2.027+2.451
TTM-0.939-2.527+1.588
YOY-0.017-3.733+3.716
3Y-0.282-3.717+3.435
5Y-0.278-6.036+5.758
10Y-0.807-6.649+5.842
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is -0.795. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.573. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.762. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.795MRQ-0.573-0.223
MRQ-0.573TTM-1.762+1.189
TTM-1.762YOY-0.034-1.728
TTM-1.7625Y-0.824-0.938
5Y-0.82410Y-1.364+0.541
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.795-3.007+2.212
MRQ-0.573-2.704+2.131
TTM-1.762-3.627+1.865
YOY-0.034-4.334+4.300
3Y-0.637-5.070+4.433
5Y-0.824-8.532+7.708
10Y-1.364-9.305+7.941
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Atara Biotherapeutics Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -1.17 means the investor is paying $-1.17Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is -1.626. Based on the equity, the company is expensive. -2
  • The MRQ is -1.170. Based on the equity, the company is expensive. -2
  • The TTM is -0.944. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.626MRQ-1.170-0.455
MRQ-1.170TTM-0.944-0.227
TTM-0.944YOY0.260-1.204
TTM-0.9445Y0.005-0.949
5Y0.00510Y0.282-0.277
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.6261.921-3.547
MRQ-1.1701.843-3.013
TTM-0.9442.113-3.057
YOY0.2602.467-2.207
3Y-0.1682.541-2.709
5Y0.0053.666-3.661
10Y0.2824.311-4.029
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Atara Biotherapeutics Inc.

4.8.1. Institutions holding Atara Biotherapeutics Inc

Institutions are holding 51.663% of the shares of Atara Biotherapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31EcoR1 Capital, LLC8.43460.2019573183410497.714
2025-03-31Redmile Group, LLC6.49980.24844170100
2025-03-31Vanguard Group Inc2.80710190761119796.7003
2025-03-31Bank of America Corp2.75610.0001187297-17873-8.7113
2025-03-31Acadian Asset Management LLC1.69390.001911511111439215909.8748
2025-03-31Vestal Point Capital LP1.38450.039994085-30915-24.732
2025-03-31Staley Capital Advisers Inc1.17720.0215800003000060
2025-03-31TANG CAPITAL MANAGEMENT LLC1.10650.02477519600
2025-03-31BlackRock Inc0.8947060798-48-0.0789
2025-03-31Geode Capital Management, LLC0.863505867939357.188
2025-03-31Susquehanna International Group, LLP0.6035041014410140
2025-03-31State Street Corp0.371602525300
2025-03-31Birchview Capital, LP0.32370.11352200000
2025-03-31GSA Capital Partners LLP0.28530.010419385193850
2025-03-31Renaissance Technologies Corp0.25660.000217436-49704-74.0304
2025-03-31FMR Inc0.2525017157-9542-35.7392
2025-03-31Bridgeway Capital Management, LLC0.2060.00211400000
2025-03-31Morgan Stanley - Brokerage Accounts0.1741011828-16523-58.2801
2025-03-31Northern Trust Corp0.164401117000
2025-03-31SBI Securities Co Ltd0.02070.00031404-12-0.8475
Total 30.27630.66452057458+137137+6.7%

4.9.2. Funds holding Atara Biotherapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv1.76960.000112025800
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr0.97790.00056645200
2025-04-30Fidelity Extended Market Index0.43170.000729334-281-0.9488
2025-03-31Fidelity VIP Disciplined Small Cap Init0.2390.02341623900
2025-03-31Bridgeway Ultra-Small Company Market0.2060.08491400000
2025-04-30Fidelity Total Market Index0.15580.00011058800
2025-03-31Extended Equity Market Fund K0.11220.00037626230.3025
2025-04-30Fidelity Series Total Market Index0.11110.000175533344.6267
2025-03-31Northern Trust Extended Eq Market Idx0.08750.0005594800
2025-03-31NT Ext Equity Mkt Idx Fd - L0.08750.0005594800
2025-04-30Spartan Extended Market Index Pool F0.0850.000657732815.1165
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.05840.0004396700
2025-04-30Spartan Total Market Index Pool G0.0490.0001333277930.5131
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.04540.00043088-56-1.7812
2025-04-30Fidelity Nasdaq Composite Index0.03940.00012678-171-6.0021
2025-04-30Vanguard Balanced Index Inv0.03820259500
2025-04-30Schwab Total Stock Market Index0.02420.0001164300
2025-04-30Vanguard U.S. Eq Idx Β£ Acc0.02140.0001145600
2025-03-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.0210.00051428110.7763
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.02090.0009141714170
Total 4.58120.1143311323+2337+0.8%

5.3. Insider Transactions

Insiders are holding 21.743% of the shares of Atara Biotherapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-05-16Anhco NguyenSELL32766.76
2025-05-16Yanina Grant-huertaSELL22186.76
2025-03-03Anhco NguyenSELL33317
2025-03-03Eric J HyllengrenSELL12117
2025-03-03Jill HenrichSELL10597
2024-11-18Anhco NguyenSELL166411.2
2024-11-18Eric J HyllengrenSELL136411.2
2024-11-18Jill HenrichSELL100011.2
2024-08-16Anhco NguyenSELL18216.63
2024-08-16Eric J HyllengrenSELL10706.63
2024-08-16Pascal TouchonSELL30386.63
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Income before Tax  -31,72812,679-19,049-2,877-21,9269,214-12,71250,72238,010
Net Income  -317,520298,471-19,049-2,860-21,9099,216-12,69350,70338,010
EBIT  -30,57512,788-17,787-2,956-20,7439,648-11,09550,12239,027
EBITDA  -29,18412,727-16,457-3,056-19,5138,918-10,59551,41740,822
Operating Income  -26,4968,265-18,231-3,526-21,7579,554-12,20351,00538,802
Net Income from Continuing Operations  -31,75212,703-19,049-2,860-21,9099,216-12,69350,70338,010



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets62,038
Total Liabilities117,110
Total Stockholder Equity-55,072
 As reported
Total Liabilities 117,110
Total Stockholder Equity+ -55,072
Total Assets = 62,038

Assets

Total Assets62,038
Total Current Assets27,182
Long-term Assets34,856
Total Current Assets
Cash And Cash Equivalents 13,841
Net Receivables 8,875
Other Current Assets 4,466
Total Current Assets  (as reported)27,182
Total Current Assets  (calculated)27,182
+/-0
Long-term Assets
Property Plant Equipment 32,012
Long-term Assets Other 2,844
Long-term Assets  (as reported)34,856
Long-term Assets  (calculated)34,856
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities47,892
Long-term Liabilities69,218
Total Stockholder Equity-55,072
Total Current Liabilities
Accounts payable 1,384
Other Current Liabilities 29,141
Total Current Liabilities  (as reported)47,892
Total Current Liabilities  (calculated)30,525
+/- 17,367
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt40,624
Long-term Liabilities Other 42,510
Long-term Liabilities  (as reported)69,218
Long-term Liabilities  (calculated)83,134
+/- 13,916
Total Stockholder Equity
Common Stock1
Retained Earnings -2,016,543
Other Stockholders Equity 1,961,470
Total Stockholder Equity (as reported)-55,072
Total Stockholder Equity (calculated)-55,072
+/-0
Other
Capital Stock1
Cash and Short Term Investments 13,841
Common Stock Shares Outstanding 10,851
Current Deferred Revenue15,983
Liabilities and Stockholders Equity 62,038
Net Debt 12,867
Net Invested Capital -55,072
Net Working Capital -20,710
Property Plant and Equipment Gross 33,707
Short Long Term Debt Total 26,708



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
4,290
0
0
0
51,828
62,866
58,503
54,120
106,122
169,817
161,102
340,379
324,975
312,978
300,814
284,417
263,914
241,738
244,155
229,693
217,779
473,108
492,707
442,940
391,839
324,726
274,144
364,785
342,942
299,547
428,111
405,532
588,120
529,637
456,791
449,923
468,127
397,280
436,121
368,316
376,420
302,083
246,439
188,788
165,504
165,272
117,284
142,706
109,098
62,038
62,038109,098142,706117,284165,272165,504188,788246,439302,083376,420368,316436,121397,280468,127449,923456,791529,637588,120405,532428,111299,547342,942364,785274,144324,726391,839442,940492,707473,108217,779229,693244,155241,738263,914284,417300,814312,978324,975340,379161,102169,817106,12254,12058,50362,86651,8280004,290
   > Total Current Assets 
0
4,207
0
0
51,808
62,291
57,085
52,022
106,026
169,691
160,634
340,235
324,597
311,741
298,883
282,230
260,553
235,318
222,492
206,217
172,190
413,614
425,070
372,976
321,489
250,830
201,139
293,418
272,992
229,217
358,987
339,432
523,273
464,307
392,325
369,497
384,621
314,389
346,984
283,046
295,080
224,182
172,320
118,696
101,869
106,434
62,410
91,855
64,894
27,182
27,18264,89491,85562,410106,434101,869118,696172,320224,182295,080283,046346,984314,389384,621369,497392,325464,307523,273339,432358,987229,217272,992293,418201,139250,830321,489372,976425,070413,614172,190206,217222,492235,318260,553282,230298,883311,741324,597340,235160,634169,691106,02652,02257,08562,29151,808004,2070
       Cash And Cash Equivalents 
4,207
-4,207
0
0
51,615
39,754
31,779
25,703
21,897
71,329
26,190
54,466
23,746
22,056
26,356
46,013
47,968
62,430
64,237
60,493
79,223
90,495
103,203
66,028
60,698
56,168
59,159
94,431
74,317
70,203
74,511
62,620
200,404
151,097
123,856
113,209
106,084
101,669
70,688
65,114
92,942
48,741
45,898
64,791
25,987
35,233
31,314
46,453
25,030
13,841
13,84125,03046,45331,31435,23325,98764,79145,89848,74192,94265,11470,688101,669106,084113,209123,856151,097200,40462,62074,51170,20374,31794,43159,15956,16860,69866,028103,20390,49579,22360,49364,23762,43047,96846,01326,35622,05623,74654,46626,19071,32921,89725,70331,77939,75451,61500-4,2074,207
       Short-term Investments 
0
8,414
0
0
0
22,277
24,719
25,996
82,219
95,367
128,841
279,799
296,736
284,347
268,201
232,134
207,714
168,216
152,659
139,728
86,873
316,826
313,812
298,515
248,933
181,377
130,976
188,491
184,792
144,428
273,201
264,565
300,255
284,064
249,524
244,036
264,984
200,142
260,623
200,290
149,877
156,666
107,744
37,617
25,884
11,152
3,978
20,736
17,466
0
017,46620,7363,97811,15225,88437,617107,744156,666149,877200,290260,623200,142264,984244,036249,524284,064300,255264,565273,201144,428184,792188,491130,976181,377248,933298,515313,812316,82686,873139,728152,659168,216207,714232,134268,201284,347296,736279,799128,84195,36782,21925,99624,71922,2770008,4140
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
800
800
1,250
9,610
700
400
986
668
637
249
40,221
397
507
163
34,108
35,834
2,422
1,335
1,482
8,875
8,8751,4821,3352,42235,83434,10816350739740,2212496376689864007009,6101,250800800000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,586
5,340
7,861
6,591
9,706
16,084
18,749
13,980
10,655
0
010,65513,98018,74916,0849,7066,5917,8615,3401,5860000000000000000000000000000000000000000
   > Long-term Assets 
0
-4,207
0
0
20
575
1,418
2,098
96
126
468
144
378
1,237
1,931
2,187
3,361
6,420
21,663
23,476
45,589
59,494
67,637
69,964
70,350
73,896
73,005
71,367
69,950
70,330
69,124
66,100
64,847
65,330
64,466
80,426
83,506
82,891
89,137
85,270
81,340
77,901
74,119
70,092
63,635
58,838
54,874
50,851
44,204
34,856
34,85644,20450,85154,87458,83863,63570,09274,11977,90181,34085,27089,13782,89183,50680,42664,46665,33064,84766,10069,12470,33069,95071,36773,00573,89670,35069,96467,63759,49445,58923,47621,6636,4203,3612,1871,9311,237378144468126962,0981,4185752000-4,2070
       Property Plant Equipment 
9
0
0
0
8
8
11
14
48
47
42
46
270
1,148
1,830
2,085
3,259
4,400
20,287
22,176
44,129
58,194
66,075
68,279
68,576
72,160
71,486
69,901
68,183
68,133
66,908
64,023
62,820
63,401
62,577
78,556
79,939
28,042
81,910
78,104
74,322
70,995
67,544
63,803
58,791
54,970
51,265
47,494
41,101
32,012
32,01241,10147,49451,26554,97058,79163,80367,54470,99574,32278,10481,91028,04279,93978,55662,57763,40162,82064,02366,90868,13368,18369,90171,48672,16068,57668,27966,07558,19444,12922,17620,2874,4003,2592,0851,8301,148270464247481411880009
       Long-term Assets Other 
0
-4,207
0
0
12
567
1,407
2,084
48
79
426
98
108
89
101
102
102
2,020
1,376
1,300
1,460
1,300
1,562
1,685
1,774
1,736
1,519
1,466
1,767
2,197
2,216
2,077
2,027
729
689
670
2,367
53,649
7,227
7,166
7,018
6,906
6,575
6,289
4,844
3,868
3,609
3,357
3,103
2,844
2,8443,1033,3573,6093,8684,8446,2896,5756,9067,0187,1667,22753,6492,3676706897292,0272,0772,2162,1971,7671,4661,5191,7361,7741,6851,5621,3001,4601,3001,3762,020102102101891089842679482,0841,4075671200-4,2070
> Total Liabilities 
1,306
0
0
0
62,845
77,570
2,280
77,149
2,940
3,723
11,847
6,631
9,875
9,144
10,569
14,215
10,178
8,604
23,011
23,737
39,915
33,924
40,208
39,886
52,982
40,792
41,865
46,343
52,161
46,725
46,986
51,597
125,781
130,600
125,253
139,782
188,513
172,964
178,642
181,203
249,780
237,123
238,985
239,626
264,735
263,580
228,152
233,245
206,381
117,110
117,110206,381233,245228,152263,580264,735239,626238,985237,123249,780181,203178,642172,964188,513139,782125,253130,600125,78151,59746,98646,72552,16146,34341,86540,79252,98239,88640,20833,92439,91523,73723,0118,60410,17814,21510,5699,1449,8756,63111,8473,7232,94077,1492,28077,57062,8450001,306
   > Total Current Liabilities 
1,302
0
0
0
1,524
2,788
2,101
2,412
2,724
3,514
11,644
6,450
9,709
8,860
10,006
13,688
9,675
7,805
11,481
16,516
27,646
21,049
27,234
27,000
39,979
25,175
25,803
30,706
36,743
31,520
31,684
36,055
82,901
84,194
88,830
86,150
105,786
101,562
65,688
72,244
78,916
67,876
74,552
79,089
142,226
180,690
148,267
155,979
134,574
47,892
47,892134,574155,979148,267180,690142,22679,08974,55267,87678,91672,24465,688101,562105,78686,15088,83084,19482,90136,05531,68431,52036,74330,70625,80325,17539,97927,00027,23421,04927,64616,51611,4817,8059,67513,68810,0068,8609,7096,45011,6443,5142,7242,4122,1012,7881,5240001,302
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
10,300
10,300
0
587
643
0
0
1,581
0
0
0
1,985
23,441
28,194
29,114
2,753
0
31,442
837
13,640
25,220
12,954
13,296
12,179
14,032
13,999
14,658
13,917
0
013,91714,65813,99914,03212,17913,29612,95425,22013,64083731,44202,75329,11428,19423,4411,9850001,58100643587010,30010,30050000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
10,300
10,300
0
0
643
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000006430010,30010,30050000000000000000000000
       Accounts payable 
121
0
0
0
606
1,402
577
569
440
794
1,703
1,853
1,445
1,896
3,235
4,463
2,778
2,204
5,243
5,539
14,711
6,098
6,545
6,193
3,719
6,168
6,420
5,155
7,963
8,079
5,106
5,190
7,118
17,355
12,301
16,543
17,368
11,945
12,799
11,296
6,871
5,068
4,138
6,511
3,684
2,854
5,253
2,146
4,367
1,384
1,3844,3672,1465,2532,8543,6846,5114,1385,0686,87111,29612,79911,94517,36816,54312,30117,3557,1185,1905,1068,0797,9635,1556,4206,1683,7196,1936,5456,09814,7115,5395,2432,2042,7784,4633,2351,8961,4451,8531,7037944405695771,402606000121
       Other Current Liabilities 
1,174
0
0
0
763
1,323
1,461
1,780
2,283
2,719
9,940
4,596
8,264
6,964
6,771
9,225
6,897
5,601
6,238
10,977
12,935
14,951
20,689
20,807
35,673
19,007
19,383
25,551
27,199
23,441
26,578
30,865
40,343
31,342
35,561
38,381
44,905
38,674
51,218
58,286
50,405
27,664
45,511
47,671
48,530
40,650
21,433
15,536
21,198
29,141
29,14121,19815,53621,43340,65048,53047,67145,51127,66450,40558,28651,21838,67444,90538,38135,56131,34240,34330,86526,57823,44127,19925,55119,38319,00735,67320,80720,68914,95112,93510,9776,2385,6016,8979,2256,7716,9648,2644,5969,9402,7192,2831,7801,4611,3237630001,174
   > Long-term Liabilities 
0
0
0
0
61,321
74,782
179
74,737
216
209
203
181
166
284
563
527
503
799
11,530
7,221
12,269
12,875
12,974
12,886
13,003
15,617
16,062
15,637
15,418
15,205
15,302
15,542
42,880
46,406
36,423
53,632
82,727
71,402
112,954
108,959
170,864
169,247
164,433
160,537
122,509
82,890
79,885
77,266
71,807
69,218
69,21871,80777,26679,88582,890122,509160,537164,433169,247170,864108,959112,95471,40282,72753,63236,42346,40642,88015,54215,30215,20515,41815,63716,06215,61713,00312,88612,97412,87512,2697,22111,53079950352756328416618120320921674,73717974,78261,3210000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
196
141
85
244
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000244851411960000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-500
-10,300
-10,300
0
-587
13,794
14,919
14,532
14,136
13,809
13,420
13,129
13,041
-10,872
-16,012
-4,540
22,765
17,453
32,557
60,235
58,064
29,698
51,754
48,508
45,693
42,197
38,703
35,243
29,914
40,624
40,62429,91435,24338,70342,19745,69348,50851,75429,69858,06460,23532,55717,45322,765-4,540-16,012-10,87213,04113,12913,42013,80914,13614,53214,91913,794-5870-10,300-10,300-50000000000000000000000
       Warrants
0
0
0
0
0
0
0
149,144
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000149,1440000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
165
216
209
203
181
0
0
0
0
0
0
0
0
0
0
0
0
0
15,617
16,062
15,637
15,418
15,205
15,302
15,542
42,880
46,406
1,771
53,632
1,501
71,402
5,626
108,959
170,864
169,247
164,433
4,848
39,254
39,974
40,615
41,553
41,893
42,510
42,51041,89341,55340,61539,97439,2544,848164,433169,247170,864108,9595,62671,4021,50153,6321,77146,40642,88015,54215,30215,20515,41815,63716,06215,61700000000000001812032092161650000000
> Total Stockholder Equity
2,984
2,984
0
0
-11,017
-14,704
56,223
-23,029
103,182
166,094
149,255
333,748
315,100
303,834
290,245
270,202
253,736
233,134
221,144
205,956
177,864
439,184
452,499
403,054
338,857
283,934
232,279
318,442
290,781
252,822
381,125
353,935
462,339
399,037
331,538
310,141
279,614
224,316
257,479
187,113
126,640
64,960
7,454
-50,838
-99,231
-98,308
-110,868
-90,539
-97,283
-55,072
-55,072-97,283-90,539-110,868-98,308-99,231-50,8387,45464,960126,640187,113257,479224,316279,614310,141331,538399,037462,339353,935381,125252,822290,781318,442232,279283,934338,857403,054452,499439,184177,864205,956221,144233,134253,736270,202290,245303,834315,100333,748149,255166,094103,182-23,02956,223-14,704-11,017002,9842,984
   Common Stock
1
0
0
0
1
0
1
-19,909
2
2
2
3
3
3
3
3
3
3
3
3
3
4
5
5
5
5
5
5
6
6
7
8
8
8
8
9
9
9
9
9
10
10
10
10
11
12
0
1
1
1
111012111010101099999888876655555543333333333222-19,9091010001
   Retained Earnings Total Equity0000000-1,838,903-1,767,795-1,693,024-1,618,452-1,534,361-1,552,827-1,464,722-1,371,373-1,286,709-1,202,916-1,124,581-1,043,274-968,926-891,470-817,961-739,465-667,570-593,242-527,349-447,337-388,976-338,093-296,650-261,337-230,241-202,813-177,159-158,924-133,551-114,671-98,110-76,862-64,994-50,049-40,889-30,3620000000
   Accumulated Other Comprehensive Income 
0
-3,727
0
0
-335
-11
0
-11
-100
-18
-66
51
-518
51
193
35
-183
-152
-114
-88
-151
-524
-505
-449
-340
38
173
233
220
204
810
527
296
161
62
24
-368
-1,892
-2,618
-2,959
-2,067
-1,237
-933
-571
-204
-55
-14
22
8
0
0822-14-55-204-571-933-1,237-2,067-2,959-2,618-1,892-368246216129652781020422023317338-340-449-505-524-151-88-114-152-1833519351-51851-66-18-100-110-11-33500-3,7270
   Capital Surplus 
0
0
0
0
0
0
0
7,344
144,169
216,159
214,313
410,556
413,725
418,451
423,600
429,088
431,075
436,096
451,496
467,378
474,662
777,797
841,975
850,835
866,541
877,133
899,671
1,057,669
1,108,516
1,144,082
1,349,234
1,396,674
1,586,616
1,601,784
1,618,177
1,681,481
1,744,695
1,779,026
1,794,449
1,808,515
1,821,721
1,833,982
1,847,280
0
0
0
0
0
0
0
00000001,847,2801,833,9821,821,7211,808,5151,794,4491,779,0261,744,6951,681,4811,618,1771,601,7841,586,6161,396,6741,349,2341,144,0821,108,5161,057,669899,671877,133866,541850,835841,975777,797474,662467,378451,496436,096431,075429,088423,600418,451413,725410,556214,313216,159144,1697,3440000000
   Treasury Stock00000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
-58,891
79,811
84,477
-12,565
144,169
216,159
214,313
410,556
413,725
418,451
423,600
429,088
431,075
436,096
451,496
467,378
474,662
777,797
841,975
850,835
866,541
877,133
899,671
1,057,669
1,108,516
1,144,082
1,349,234
1,396,674
1,586,616
1,601,784
1,618,177
1,681,481
1,744,695
1,779,026
1,794,449
1,808,515
1,821,721
1,833,982
1,847,280
1,858,423
1,870,112
1,902,637
1,909,097
1,951,298
1,957,261
1,961,470
1,961,4701,957,2611,951,2981,909,0971,902,6371,870,1121,858,4231,847,2801,833,9821,821,7211,808,5151,794,4491,779,0261,744,6951,681,4811,618,1771,601,7841,586,6161,396,6741,349,2341,144,0821,108,5161,057,669899,671877,133866,541850,835841,975777,797474,662467,378451,496436,096431,075429,088423,600418,451413,725410,556214,313216,159144,169-12,56584,47779,811-58,8910000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue128,940
Cost of Revenue-21,009
Gross Profit107,931107,931
 
Operating Income (+$)
Gross Profit107,931
Operating Expense-191,369
Operating Income-83,438-83,438
 
Operating Expense (+$)
Research Development151,483
Selling General Administrative39,886
Selling And Marketing Expenses0
Operating Expense191,369191,369
 
Net Interest Income (+$)
Interest Income2,110
Interest Expense-4,615
Other Finance Cost-0
Net Interest Income-2,505
 
Pretax Income (+$)
Operating Income-83,438
Net Interest Income-2,505
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-85,415-81,461
EBIT - interestExpense = -85,415
-85,415
-80,788
Interest Expense4,615
Earnings Before Interest and Taxes (EBIT)-80,800-80,800
Earnings Before Interest and Taxes (EBITDA)-75,749
 
After tax Income (+$)
Income Before Tax-85,415
Tax Provision--12
Net Income From Continuing Ops-85,403-85,403
Net Income-85,403
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses212,378
Total Other Income/Expenses Net-1,9772,505
 

Technical Analysis of Atara Biotherapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Atara Biotherapeutics Inc. The general trend of Atara Biotherapeutics Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Atara Biotherapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Atara Biotherapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Atara Biotherapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 9.6825 < 11.06 < 18.25.

The bearish price targets are: 7.51 > 6.39 > 6.2474.

Know someone who trades $ATRA? Share this with them.πŸ‘‡

Atara Biotherapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Atara Biotherapeutics Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Atara Biotherapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Atara Biotherapeutics Inc. The current macd is 0.0485.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Atara Biotherapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Atara Biotherapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Atara Biotherapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Atara Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAtara Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Atara Biotherapeutics Inc. The current adx is 20.06.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Atara Biotherapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Atara Biotherapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Atara Biotherapeutics Inc. The current sar is 7.51.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Atara Biotherapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Atara Biotherapeutics Inc. The current rsi is 54.59. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Atara Biotherapeutics Inc Daily Relative Strength Index (RSI) ChartAtara Biotherapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Atara Biotherapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Atara Biotherapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Atara Biotherapeutics Inc Daily Stochastic Oscillator ChartAtara Biotherapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Atara Biotherapeutics Inc. The current cci is -26.8003085.

Atara Biotherapeutics Inc Daily Commodity Channel Index (CCI) ChartAtara Biotherapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Atara Biotherapeutics Inc. The current cmo is 11.64.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Atara Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAtara Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Atara Biotherapeutics Inc. The current willr is -50.33557047.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Atara Biotherapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Atara Biotherapeutics Inc Daily Williams %R ChartAtara Biotherapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Atara Biotherapeutics Inc. The current atr is 0.52388004.

Atara Biotherapeutics Inc Daily Average True Range (ATR) ChartAtara Biotherapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Atara Biotherapeutics Inc. The current obv is 1,292,847.

Atara Biotherapeutics Inc Daily On-Balance Volume (OBV) ChartAtara Biotherapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Atara Biotherapeutics Inc. The current mfi is 39.66.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Atara Biotherapeutics Inc Daily Money Flow Index (MFI) ChartAtara Biotherapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Atara Biotherapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-24BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-03BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-06-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Atara Biotherapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Atara Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.593
Ma 20Greater thanMa 508.339
Ma 50Greater thanMa 1007.737
Ma 100Greater thanMa 2007.319
OpenGreater thanClose7.880
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Atara Biotherapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Atara Biotherapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Atara Biotherapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Atara Biotherapeutics Inc

I send you an email if I find something interesting about Atara Biotherapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Atara Biotherapeutics Inc.

Receive notifications about Atara Biotherapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.